RxSight Inc
Research RxSight Inc (RXST) on Bullrun: market cap USD 266.15M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRXST
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 266.15M
- Financial periodQ2 2026
- RevenueUSD 33.74M
- Net income-USD 12.10M
- Free cash flow-USD 11.49M
- Gross margin76.7%
Valuation Snapshot
latest market cap is USD 266.15M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 134.48M | -USD 39 | -USD 19.34M | 76.6% | -0.95 | USD 19.95M | USD 11.04M | USD 275.68M |
| FY2024 | USD 139.93M | -USD 28 | -USD 22.39M | 70.7% | -0.71 | USD 16.71M | USD 12.30M | USD 281.24M |
| FY2023 | USD 89.08M | -USD 49 | -USD 46.41M | 60.4% | -1.41 | USD 9.69M | USD 0 | USD 160.36M |
| FY2022 | USD 49.01M | -USD 67 | -USD 61.24M | 43.5% | -2.41 | USD 11.83M | USD 40.17M | USD 89.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 266.15M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 429.74M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.39B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.45B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 351.23M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 307.88M | n/a | n/a | n/a |
About RxSight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is RxSight Inc's market cap?
RxSight Inc's market capitalization is USD 266.15M.
What does RxSight Inc do?
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.